Dolutegravir and Disease progression - a phase IV clinical study of FDA data

Summary:

Disease progression is reported as a side effect among people who take Dolutegravir (dolutegravir), especially for people who are male, 30-39 old, also take Lamivudine, and have Hiv infection.

The phase IV clinical study analyzes which people have Disease progression when taking Dolutegravir. It is created by eHealthMe based on reports of 7,061 people who have side effects when taking Dolutegravir from the FDA, and is updated regularly.

What is Dolutegravir?

Dolutegravir has active ingredients of dolutegravir. eHealthMe is studying from 7,071 Dolutegravir users. Check the latest studies of Dolutegravir.

What is Disease progression?

Disease progression is found to be associated with 1,800 drugs and 2,255 conditions by eHealthMe. Check the latest studies of Disease progression.

On Jul, 26, 2026

7,061 people reported to have side effects when taking Dolutegravir.
Among them, 26 people (0.37%) have Disease progression.

Could Dolutegravir cause Disease progression?

Among these 26 people:

What is the gender of people who have Disease progression when taking Dolutegravir? *

female: 50 %
male: 50 %

What is the age of people who have Disease progression when taking Dolutegravir? *

What are other drugs people take besides Dolutegravir? *

What are other side effects people have besides Disease progression? *

Dyspnea (difficult or laboured breathing): 6 people, 23.08%
Fever: 6 people, 23.08%
Diarrhea: 3 people, 11.54%
Retinal Toxicity (retina damage due to medication): 3 people, 11.54%
Drug Resistance (reduction in effectiveness of a drug): 3 people, 11.54%
Abdominal Pain: 3 people, 11.54%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 2 people, 7.69%
Angioedema (rapid swelling of the dermis): 2 people, 7.69%
Nosebleed (bleeding from nose): 2 people, 7.69%
Muscle Aches (muscle pain): 2 people, 7.69%

What are the existing conditions these people have? *

Hiv Infection: 17 people, 65.38%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 3 people, 11.54%
Meningitis Tuberculous (a bacterial infection of the membranes covering the brain and spinal cord (meninges)): 3 people, 11.54%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 2 people, 7.69%
Oedema (fluid collection in tissue): 2 people, 7.69%
Malignant Melanoma (skin cancer rises from melancytes): 2 people, 7.69%
Pneumonia Cryptococcal (pneumonia caused by cryptococcal infection): 1 person, 3.85%
Myelopathy (any neurologic deficit related to the spinal cord): 1 person, 3.85%
Mycobacterial Infection: 1 person, 3.85%
Meningitis Cryptococcal (bacterial inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges): 1 person, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Dolutegravir and have Disease progression?

- Check whether Disease progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dolutegravir:

Dolutegravir (7,071 reports)

Browse all side effects of Dolutegravir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Disease progression:

Disease progression (1,800 drugs)

Browse all the conditions that are associated with Disease progression:

Disease progression (2,255 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dolutegravir (the active ingredients of Dolutegravir) and Dolutegravir (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.